We can read a patient’s genome in a day. We can design a therapy in an hour.
And then… we spend six weeks faxing, phoning, and re-keying our way to the infusion chair.
That’s the gap. And here’s the architecture that closes it:
Claude as the reasoning layer
UiPath as the execution layer
The Reality of Genomic Therapy
Every health system I’ve seen starts in the same place:
-
Buy the sequencer
-
Hire the bioinformaticians
-
Stand up the tumor board
And every one of them hits the same wall. Not in the science, but in the seams between the 20+ organizations that must move in lockstep before a personalized therapy reaches a human being.
A CAR-T order touches:
Hospital EMR
Reference lab
Payer portal
Manufacturing MES
Cryogenic courier
Pharmacy system
Regulatory record-keeping
None of them share a data model. Most still exchange work through PDFs, portals, and people. The therapy is personalized. The supply chain isn’t.
Why “Add AI” Keeps Disappointing Boards
A brilliant model that reads a variant call file and drops its answer into a clinician’s inbox hasn’t solved the bottleneck-it’s just moved it.
Intelligence without execution is a very expensive second opinion.
Where the Days Actually Go
We instrumented the journey. Not the PMO swimlane, but the real one—reconstructed from system logs and task mining.
The pattern is consistent:
-
Science is fast
-
Handoffs are slow
-
70% of elapsed time is queue time
-
Almost all of it sits between organizations
The Architecture That Works
It’s boring in the best way:
-
One layer reasons
-
One layer executes
-
Governance lives at the boundary
The Agent Mesh
Ten specialized agents, each with a narrow remit, a defined evidence base, and a confidence threshold. They don’t chat freely; they exchange typed artifacts through Maestro, which alone knows the patient’s step.
The Swimlane
Ends the arguments. Shows clinicians exactly where their signature still matters. Shows operating committees exactly which queues disappear.
Design for the Day
Credibility isn’t proven on the happy path. It’s proven when a courier’s cryoshipper logs −118 °C for forty minutes at 2 a.m. on a Sunday.
In a well-built system:
-
The cold-chain agent correlates the excursion against the stability profile
-
Maestro pages the QP
-
The manufacturer’s slot is re-held
-
The patient’s regimen is flagged before the day shift arrives
The scramble doesn’t happen.
Proving It, Shipping It
Validation kills timelines when discovered late. Treat the model like a regulated instrument:
-
Frozen golden set of de-identified cases
-
Adjudicated ground truth
-
Drift and hallucination checks as gating criteria
Everything else is conventional enterprise practice: Git, Azure DevOps, vaults for secrets, Dev → QA → UAT → Pre-Prod → Prod, canary rollouts, hypercare with a named clinical safety officer.
If your CI/CD story here looks different from the rest of your estate, you’ve built something you can’t support.
The Funding Conversation
If you’re asked to fund “AI for precision medicine,” push back. The model is the cheapest part.
What you’re really funding is the connective tissue:
-
A durable process engine that survives a six-week patient journey
-
Integrations into systems that were never designed to cooperate
-
An audit trail solid enough for regulators
Claude gives you cognition that can read a genome and explain its reasoning to a tumor board.
UiPath gives you the execution layer that turns that reasoning into scheduled slots, released batches, authorized claims, and a patient in a chair on the right Tuesday.
Neither one gets a therapy to a patient alone. Together, they close the gap.
Leadership takeaway: Precision medicine isn’t just about smarter science. It’s about smarter systems. The winners will be those who build the connective tissue that makes personalized therapy flow at the speed of life.
@uipath | @Vibhor.Shrivastava | @Rohit_Radhakrishnan | @loginerror | @UiPath_Community